Shares of Zomedica Corp. (NYSEAMERICAN:ZOM – Get Free Report) dropped 2.2% during trading on Thursday . The stock traded as low as $0.13 and last traded at $0.14. Approximately 8,794,663 shares traded hands during trading, a decline of 48% from the average daily volume of 16,965,762 shares. The stock had previously closed at $0.14.
Wall Street Analysts Forecast Growth
Separately, Noble Financial raised Zomedica to a “strong-buy” rating in a report on Monday, November 11th.
Check Out Our Latest Analysis on ZOM
Zomedica Stock Performance
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Zomedica stock. Geode Capital Management LLC lifted its holdings in shares of Zomedica Corp. (NYSEAMERICAN:ZOM – Free Report) by 3.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,929,716 shares of the company’s stock after buying an additional 321,395 shares during the quarter. Geode Capital Management LLC owned about 1.01% of Zomedica worth $1,363,000 at the end of the most recent quarter. Institutional investors and hedge funds own 8.95% of the company’s stock.
About Zomedica
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.
See Also
- Five stocks we like better than Zomedica
- The Basics of Support and Resistance
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- How to Calculate Stock Profit
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Quiet Period Expirations Explained
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Zomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica and related companies with MarketBeat.com's FREE daily email newsletter.